A government crackdown on cheaper copies of Ozempic and similar diabetes and weight-loss drugs was intended to shut the door on that booming market. It hasn’t exactly worked out that way.

The boss of Ozempic maker Novo Nordisk lost his job yesterday after its share price plunged amid intensifying competition in the multi-billion pound fat jab market. Lars Fruergaard Jorgensen is ...

The global market for diabetes drugs used for treating obesity is expected to expand in Asia, as new players jostle with giants Eli Lilly and Novo Nordisk for a share of the multibillion-dollar ...

The Therapeutic Goods Administration has received complaints of blindness and vision loss in one eye among users of Ozempic and Wegovy, who are reluctant to ditch the weight-loss drugs.

(Reuters) -Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to ...

Weekly jabs might not sound glamorous, but Mounjaro and Ozempic are making headlines for more than just managing blood sugar. These injectable medications, originally developed for type 2 diabetes, ...